Birchview Capital, LP Castle Biosciences Inc Transaction History
Birchview Capital, LP
- $108 Million
- Q3 2024
A detailed history of Birchview Capital, LP transactions in Castle Biosciences Inc stock. As of the latest transaction made, Birchview Capital, LP holds 58,000 shares of CSTL stock, worth $1.54 Million. This represents 1.53% of its overall portfolio holdings.
Number of Shares
58,000
Previous 34,000
70.59%
Holding current value
$1.54 Million
Previous $740,000
123.51%
% of portfolio
1.53%
Previous 0.74%
Shares
3 transactions
Others Institutions Holding CSTL
# of Institutions
202Shares Held
24.5MCall Options Held
303KPut Options Held
30.3K-
Black Rock Inc. New York, NY3.04MShares$80.7 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.83MShares$48.4 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.75MShares$46.3 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.26MShares$33.4 Million0.61% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.26MShares$33.3 Million2.85% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $697M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...